Document is current

Article History

Received: 24 April 2024

Accepted: 21 July 2024

First Online: 29 August 2024

Declarations

:

: Not applicable.

: CN has received consultant honoraria from Keosys and funding from Radius, Immedica, Thema Sinergie. CMD has received consultant honoraria from Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO and Immedica Pharma; his institution has received travel support from GE Healthcare, Sirtex. CL has received research funding from RayzeBio and consultant honoraria from Blue Earth Diagnostics Ltd. (BED, Oxford, UK) and Novartis. NW has received consultant honoraria from Novartis and SCK CEN. EZ has served consulting/advisory role and received honoraria from Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides, Menarini Stemline. MD has received speaker honoraria from BMS, GSK, Janssen, Sanofi, Stemline. FKB has received consultant honoraria from Novartis AAA, Telix pharmaceuticals and Immedica and research funding from Siemens.SB, MS, BJ, DI have no relevant financial or non-financial interests to disclose.

: This guideline summarizes the views of the EANM Oncology and Theranostics Committee. It reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.